{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T17:03:03Z","timestamp":1775581383924,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"johnson and johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Atrial fibrillation affects an estimated 33 million individuals worldwide and is a major cause of stroke, heart failure, and death. Anticoagulants substantially reduce the risk of stroke but are also associated with an increased risk of bleeding and especially intracranial hemorrhage which is the most concerning complication. Because of this, many patients are not offered anticoagulants, particularly patients at risk of falls or with a history of falls. It is unclear what anticoagulant treatment these patients should be offered. The Liverpool AF-Falls project aims to investigate this area, and this protocol for a systematic review and meta-analysis aims to define what is the most appropriate anticoagulant treatment option for the management of atrial fibrillation patients at risk of falls or with a history of falls.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This systematic review and meta-analysis will include randomized and non-randomized studies evaluating the safety and efficacy of different anticoagulant treatments (vitamin K antagonist and non-vitamin K antagonist oral anti-coagulant). Bibliographic databases (Cochrane Central Register of Controlled Trials, CINAHL, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>, Embase, MEDLINE, Scopus and Web of Science) will be searched according to a pre-specified search strategy. Titles, abstracts, and full texts will be assessed by two independent reviewers and disagreements resolved with a third independent reviewer. The Cochrane Risk of Bias tool 2 (RoB 2) will be used to assess the risk of bias in randomized trials, and the Risk Of Bias In Non-randomized Studies - of Interventions (ROBINS-I) tool will be used for non-randomized studies. A pairwise meta-analysis based on the fixed and random-effects models will be conducted. Publication bias will be evaluated with a funnel plot and Egger\u2019s test. Heterogeneity will be assessed with the <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> statistic. If conditions for indirect comparison are met and sufficient data are available, a network meta-analysis will be conducted using frequentist and Bayesian methodologies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This review will be the first to summarize direct and indirect evidence on the safety and efficacy of anticoagulant treatments in atrial fibrillation patients at risk of falls or with a history of falls. The findings will be important to patients, clinicians, and health policy-makers to inform best practices in the use of these treatments.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Systematic review registration<\/jats:title>\n                <jats:p>PROSPERO registry number: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=201086\">CRD42020201086<\/jats:ext-link><\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13643-022-01937-0","type":"journal-article","created":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T06:10:28Z","timestamp":1649398228000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The management of anticoagulants in patients with atrial fibrillation and history of falls or risk of falls: protocol for a systematic review and meta-analysis"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0412-249X","authenticated-orcid":false,"given":"Thibaut","family":"Galvain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruaraidh","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Donegan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo","family":"Lisboa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Czanner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,8]]},"reference":[{"issue":"8","key":"1937_CR1","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1136\/heart.89.8.939","volume":"89","author":"V Markides","year":"2003","unstructured":"Markides V, Schilling RJ. Atrial fibrillation: classification, pathophysiology, mechanisms and drug treatment. Heart. 2003;89(8):939\u201343.","journal-title":"Heart."},{"issue":"8","key":"1937_CR2","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","volume":"129","author":"SS Chugh","year":"2014","unstructured":"Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation. 2014;129(8):837\u201347.","journal-title":"Circulation."},{"issue":"6","key":"1937_CR3","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1161\/01.STR.0000166053.83476.4a","volume":"36","author":"C Marini","year":"2005","unstructured":"Marini C, De Santis F, Sacco S, Russo T, Olivieri L, Totaro R, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005;36(6):1115\u20139.","journal-title":"Stroke."},{"key":"1937_CR4","doi-asserted-by":"publisher","unstructured":"Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med.\u00a01994;154(13):1449\u201357. https:\/\/doi.org\/10.1001\/archinte.1994.00420130036007.","DOI":"10.1001\/archinte.1994.00420130036007"},{"issue":"9","key":"1937_CR5","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.117.309732","volume":"120","author":"L Staerk","year":"2017","unstructured":"Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH. Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes. Circ Res. 2017;120(9):1501\u201317.","journal-title":"Circ Res"},{"issue":"10","key":"1937_CR6","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/ene.13742","volume":"25","author":"AH Katsanos","year":"2018","unstructured":"Katsanos AH, Schellinger PD, K\u00f6hrmann M, Filippatou A, Gurol ME, Caso V, et al. Fatal oral anticoagulant-related intracranial hemorrhage: a systematic review and meta-analysis. Eur J Neurol. 2018;25(10):1299\u2013302.","journal-title":"Eur J Neurol"},{"issue":"5","key":"1937_CR7","doi-asserted-by":"publisher","first-page":"e63479","DOI":"10.1371\/journal.pone.0063479","volume":"8","author":"AK Kakkar","year":"2013","unstructured":"Kakkar AK, Mueller I, Bassand J-P, Fitzmaurice DA, Goldhaber SZ, Goto S, et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One. 2013;8(5):e63479.","journal-title":"PLoS One"},{"issue":"1","key":"1937_CR8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/jgs.13200","volume":"63","author":"O Bahri","year":"2015","unstructured":"Bahri O, Roca F, Lechani T, Druesne L, Jouanny P, Serot J-M, et al. Underuse of oral anticoagulation for individuals with atrial fibrillation in a nursing home setting in France: comparisons of resident characteristics and physician attitude. J Am Geriatr Soc. 2015;63(1):71\u20136.","journal-title":"J Am Geriatr Soc"},{"issue":"8","key":"1937_CR9","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.amjmed.2012.01.033","volume":"125","author":"J Donz\u00e9","year":"2012","unstructured":"Donz\u00e9 J, Clair C, Hug B, Rodondi N, Waeber G, Cornuz J, et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med. 2012;125(8):773\u20138.","journal-title":"Am J Med"},{"issue":"7","key":"1937_CR10","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/archinte.159.7.677","volume":"159","author":"M Man-Son-Hing","year":"1999","unstructured":"Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med. 1999;159(7):677\u201385.","journal-title":"Arch Intern Med"},{"issue":"38","key":"1937_CR11","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893\u2013962.","journal-title":"Eur Heart J"},{"key":"1937_CR12","doi-asserted-by":"publisher","first-page":"583311","DOI":"10.3389\/fphar.2020.583311","volume":"11","author":"M Grymonprez","year":"2020","unstructured":"Grymonprez M, Steurbaut S, De Backer TL, Petrovic M, Lahousse L. Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-analysis. Front Pharmacol. 2020;11:583311.","journal-title":"Front Pharmacol"},{"key":"1937_CR13","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane Handbook for systematic reviews of interventions version 6.2 (updated February 2021) [Internet]. Cochrane, 2021; Available from: www.training.cochrane.org\/handbook"},{"key":"1937_CR14","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.\u00a0https:\/\/doi.org\/10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"issue":"11","key":"1937_CR15","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384.","journal-title":"Ann Intern Med"},{"issue":"11","key":"1937_CR16","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.jacc.2016.06.034","volume":"68","author":"J Steffel","year":"2016","unstructured":"Steffel J, Giugliano RP, Braunwald E, Murphy SA, Mercuri M, Choi Y, et al. Edoxaban versus warfarin in atrial fibrillation patients at risk of falling: ENGAGE AF\u2013TIMI 48 analysis. J Am Coll Cardiol. 2016;68(11):1169\u201378.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1937_CR17","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C, the Subcommittee on control of anticoagulation of the scientific and standardization committee of the international society on thrombosis and haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients: definitions of major bleeding in clinical studies. J Thromb Haemost. 2005;3(4):692\u20134.","journal-title":"J Thromb Haemost"},{"issue":"11","key":"1937_CR18","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","volume":"13","author":"S Kaatz","year":"2015","unstructured":"Kaatz S, Ahmad D, Spyropoulos AC, Schulman S, the Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13(11):2119\u201326.","journal-title":"J Thromb Haemost"},{"key":"1937_CR19","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ."},{"key":"1937_CR20","unstructured":"Risk of bias tools - Current version of RoB 2 [Internet]. [cited 2022 Mar 18]. Available from: https:\/\/sites.google.com\/site\/riskofbiastool\/welcome\/rob-2-0-tool\/current-version-of-rob-2"},{"key":"1937_CR21","doi-asserted-by":"publisher","unstructured":"Sterne JA, Hern\u00c3\u00a1n MA, Reeves BC, Savovi\u00c4\u2021 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919.","DOI":"10.1136\/bmj.i4919"},{"key":"1937_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.","journal-title":"Trials."},{"issue":"3","key":"1937_CR23","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.jvs.2019.05.037","volume":"71","author":"GA Antoniou","year":"2020","unstructured":"Antoniou GA, Antoniou SA, Smith CT. A guide on meta-analysis of time-to-event outcomes using aggregate data in vascular and endovascular surgery. J Vasc Surg. 2020;71(3):1002\u20135.","journal-title":"J Vasc Surg"},{"issue":"3","key":"1937_CR24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1136\/eb-2014-101900","volume":"17","author":"D Mavridis","year":"2014","unstructured":"Mavridis D, Chaimani A, Efthimiou O, Leucht S, Salanti G. Addressing missing outcome data in meta-analysis. Evid Based Ment Health. 2014;17(3):85\u20139.","journal-title":"Evid Based Ment Health"},{"issue":"7414","key":"1937_CR25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ."},{"issue":"8746","key":"1937_CR26","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/0140-6736(91)90201-Y","volume":"337","author":"PJ Easterbrook","year":"1991","unstructured":"Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337(8746):867\u201372.","journal-title":"Lancet."},{"issue":"3","key":"1937_CR27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388.","journal-title":"Control Clin Trials"},{"key":"1937_CR28","doi-asserted-by":"crossref","unstructured":"Riley RD, Higgins JPT, Deeks JJ. Interpretation of random effects meta-analyses. BMJ. 2011;342 [cited 2020 Jul 26]. Available from: https:\/\/www.bmj.com\/content\/342\/bmj.d549.","DOI":"10.1136\/bmj.d549"},{"issue":"4","key":"1937_CR29","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/jrsm.1085","volume":"4","author":"S Donegan","year":"2013","unstructured":"Donegan S, Williamson P, D\u2019Alessandro U, Tudur SC. Assessing key assumptions of network meta-analysis: a review of methods: assessing assumptions of network meta-analysis. Res Synth Methods. 2013;4(4):291\u2013323.","journal-title":"Res Synth Methods"},{"key":"1937_CR30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jclinepi.2016.11.015","volume":"83","author":"A Chaimani","year":"2017","unstructured":"Chaimani A, Caldwell DM, Li T, Higgins JPT, Salanti G. Additional considerations are required when preparing a protocol for a systematic review with multiple interventions. J Clin Epidemiol. 2017;83:65\u201374.","journal-title":"J Clin Epidemiol"},{"key":"1937_CR31","unstructured":"Harrer M, Cuijpers P, Ebert D. Doing meta-analysis in R. 2019 [cited 2020 Apr 23]; Available from: https:\/\/bookdown.org\/MathiasHarrer\/Doing_Meta_Analysis_in_R\/"},{"issue":"4","key":"1937_CR32","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383\u201394.","journal-title":"J Clin Epidemiol"},{"issue":"7650","key":"1937_CR33","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136.","journal-title":"BMJ."},{"key":"1937_CR34","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jclinepi.2018.01.012","volume":"111","author":"HJ Sch\u00fcnemann","year":"2019","unstructured":"Sch\u00fcnemann HJ, Cuello C, Akl EA, Mustafa RA, Meerpohl JJ, Thayer K, et al. GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in non-randomized studies should be used to rate the certainty of a body of evidence. J Clin Epidemiol. 2019;111:105\u201314.","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"1937_CR35","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1136\/jech.2010.119933","volume":"65","author":"H Sch\u00fcnemann","year":"2011","unstructured":"Sch\u00fcnemann H, Hill S, Guyatt G, Akl EA, Ahmed F. The GRADE approach and Bradford Hill\u2019s criteria for causation. J Epidemiol Community Health. 2011;65(5):392\u20135.","journal-title":"J Epidemiol Community Health"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-022-01937-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-022-01937-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-022-01937-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T06:11:21Z","timestamp":1649398281000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-022-01937-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,8]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1937"],"URL":"https:\/\/doi.org\/10.1186\/s13643-022-01937-0","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,8]]},"assertion":[{"value":"18 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TG is an employee of Johnson and Johnson Medical. RH declares a financial\u2013non-personal, non-specific interest, having delivered educational workshops on health economics, medicines management and HTA for cancer specialists supported by unrestricted sponsorship by the pharmaceutical industry and an industry association (March 2019). No fees received personally. Not specific to the topic of the review. The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"63"}}